WHAT IS CLAIMED IS:

a

- 1. A vaccinia virus modified by the presence of exogenous DNA in the vaccinia genome.
- 2. A vaccinia virus as in Claim 1 wherein said exogenous DNA is expressed in a host by the production of a protein.
- 3. A vaccinia virus as in Claim 2 wherein said protein is an antigen.
- 4. A vaccinia virus as in Claim 2 wherein said exogenous DNA is a gene of herpes simplex expressed in a host by the production of thymidine kinase.
- 5. A vaccinia virus as in Claim 4 wherein said virus is free of vaccinia gene producing thymidine kinase.
- 6. A vaccinia virus as in Claim 3 wherein said antigen is influenza virus hemmagglutinin.
- 7. A vaccinia virus as in Claim 3 wherein said antigen is hepatitis B surface antigen.
- 8. A vaccinia virus as in Claim wherein said antigen is herpes simplex virus glycoprotein Q.
- 9. A vaccinia virus as in Claim 1 which is vaccinia virus VP-2, VP-3, VP-4, VP-5, VP-6, VP-7, VP-8,

VP-9, VP-10, VP-11, VP-12, VP-13, VP-14, VP-16, VP-17, VP-18, VP-22, VP-53, VP-59, or VP-60.

- 10. The method of replicating DNA in a eukaryotic cell by infecting said cell with a vaccinia virus modified to contain said DNA, said DNA being exogenous to said vaccinia virus.
- 11. A method as in Claim 10 wherein said DNA is also exogenous to said cell.
- 12. A method as in Claim 11 wherein said DNA is expressed by said cell.
- 13. A method as in Claim 12 wherein said DNA is expressed by the production by said cell of a biological product.
- 14. A method as in Claim 13 wherein said DNA which is replicated includes the herpes simplex TK gene and said biological product is thymidine kinase.
- 15. A method as in Claim 13 wherein said DNA which is replicated includes the influenza hemmagglutinin gene and said biological product is the influenza hemagglutinin antigen.
- 16. A method as in Claim 13 wherein said DNA which is replicated includes the HBsAg gene and said biological product is the hepatitis B surface antigen.

- 17. A method as in Claim 13 wherein said DNA which is replicated includes the gene for HSVgD and said biological product is the herpes simplex virus glycoprotein D.
- 18. The method of immunizing a host animal, susceptible to vaccinia virus, by inducing said animal to develop antibodies against an antigen, which method comprises inoculating said host animal with a vaccinia virus having, within the vaccinia genome, DNA exogenous to said genome and coding for said antigen.
- 19. A method as in Claim 18 wherein said vaccinia virus contains DNA coding for influenza virus hemagglutinin.
- 20. A method as in Claim 18 wherein said vaccinia virus contains DNA coding for hepatitis B surface antigen.
- 21. A method as in Claim 18 wherein said vaccinia virus contains DNA coding for herpes simplex glycoprotein D.

 $a_{\alpha}^{5}ad$